A Swissmedic licence is the mandatory federal authorisation required to manufacture, import, distribute, or sell pharmaceuticals and medical devices in Switzerland. Switzerland is home to Novartis, Roche, Lonza, and hundreds of biotech and medical device companies, with the pharmaceutical sector contributing approximately 10% of Swiss GDP. Access to this market — whether you are launching a drug, a medical device, or a diagnostic tool — runs through a single federal gateway: Swissmedic.
This guide sets out what a Swissmedic licence in Switzerland actually requires, how long it takes, and what regulatory decisions you need to make before you submit anything.
A common misconception among foreign entrants: Swissmedic does not operate a paper-only review. The agency conducts on-site inspections of manufacturing facilities, reviews batch release protocols, and verifies the qualifications of responsible persons before granting any manufacturing or import licence. Submitting a technically complete dossier is necessary but not sufficient — the operational reality must match what the documentation describes.
What Is Swissmedic?
Swissmedic is the Swiss Agency for Therapeutic Products — the federal authority responsible for authorising and supervising all therapeutic products sold or used in Switzerland. Its remit covers:
- Pharmaceuticals (prescription and OTC)
- Biological medicines, vaccines, and blood products
- Stem cell preparations
- Medical devices and in vitro diagnostics
The legal foundation sits in two instruments: the Therapeutic Products Act (HMG/LPTh) and the Medical Device Ordinance (MepV/ODim). Operating without the required Swissmedic authorisation is a criminal offence, not just a regulatory infraction. Companies entering the Swiss market must also consider the broader Swiss business licensing framework that governs regulated sectors.
Pharmaceutical Marketing Authorisation (Zulassung)
Any medicinal product that is to be sold, distributed, or commercially used in Switzerland requires a Swissmedic marketing authorisation (Zulassung). This applies to prescription drugs, OTC medicines, biologicals, biosimilars, and vaccines — regardless of whether the product already holds EU, US, or other regulatory approval.
What the Dossier Must Include
A complete application dossier submitted to Swissmedic must contain:
- Pre-clinical data: pharmacology, toxicology, and safety pharmacology studies
- Clinical trial data: efficacy and safety from controlled human studies (Phases I-III)
- Pharmaceutical quality data: composition, manufacturing process, stability, and quality controls
- Labelling: professional information (Fachinformation), patient information leaflet, and packaging text in the official Swiss languages
Swissmedic applies the Common Technical Document (CTD) format, consistent with ICH guidelines.
Authorisation Procedures and Timelines
The procedure that applies to your application depends on the product type, the novelty of the active substance, and the urgency of the public health need.
| Procedure | Applicable Products | Typical Timeline | Fee Range (CHF) |
|---|---|---|---|
| Standard procedure | New active substances, novel biologicals | 12-18 months | 80,000-200,000 |
| Accelerated procedure | Urgent public health need (e.g. pandemic response, orphan disease) | 6-12 months | 80,000-200,000 |
| Simplified procedure | Well-established substances, homeopathic preparations | 6-12 months | 15,000-50,000 |
| Generic procedure | Generics where reference product is already authorised by Swissmedic | 6-12 months | 15,000-50,000 |
Fees are set by ordinance and depend on procedure type, complexity, and whether the application requires additional expert assessment. Budget for the full range — underprepared dossiers attract queries that stop the clock and extend the timeline materially. Clock-stops are not administrative formalities: each query from Swissmedic halts the review period entirely, and the clock only restarts when the applicant provides a complete response. In practice, a single round of deficiency questions can add 3-6 months. Two rounds — which is not unusual for novel biologicals — can push a standard procedure past 24 months.
Post-Authorisation Obligations
A Swissmedic marketing authorisation is not a one-time event. Authorisation holders must:
- Report adverse reactions and safety signals under pharmacovigilance obligations
- Notify Swissmedic before making any changes to formulation, manufacturing site, or labelling (variation procedure)
- Renew the authorisation every five years
Manufacturing Licence
Every company manufacturing therapeutic products in Switzerland — whether for the Swiss market or for export — must hold a Swissmedic manufacturing licence. This applies to:
- Primary and secondary pharmaceutical manufacturers
- Manufacturers of investigational medicinal products (IMPs) for clinical trials
- Importers who repackage or relabel products on Swiss soil
GMP compliance is non-negotiable. Swissmedic conducts regular GMP inspections of manufacturing sites. Inspections can be announced or unannounced. Deficiencies that are not remediated on the agreed timeline will result in licence suspension or withdrawal.
Where a Swiss company manufactures for EU markets under the Swiss-EU Mutual Recognition Agreement (MRA), Swissmedic GMP certificates are recognised by EU competent authorities — and vice versa. This bilateral recognition is a significant practical advantage that Switzerland’s non-EU status would otherwise remove. Foreign companies that need to establish a Swiss manufacturing entity should review our guide on company formation in Switzerland.
Import Licence
Any company importing therapeutic products into Switzerland — including finished drug products, active pharmaceutical ingredients, and medical devices subject to authorisation — requires a separate Swissmedic import licence. The import licence confirms that the importer has the infrastructure, quality systems, and qualified personnel to verify that imported goods conform to Swiss requirements.
Companies holding a manufacturing licence may apply for import authorisation within the same application process.
Clinical Trial Authorisation
Clinical trials conducted in Switzerland require authorisation from two bodies: Swissmedic and the relevant cantonal ethics committee. Both must approve before the trial can start.
Switzerland aligns with ICH E6 (GCP) guidelines and has harmonised its clinical trial framework with the EU Clinical Trials Regulation (EU CTR). Key procedural points:
- Swissmedic reviews the quality and pre-clinical/clinical data package for the investigational product
- The ethics committee reviews the protocol, patient information, and consent procedures
- Phase I trials involving healthy volunteers require Swissmedic authorisation even without a cantonal ethics requirement in some cantons — confirm jurisdiction-specific rules early
- Substantial protocol amendments require a variation submission to both Swissmedic and the ethics committee
Switzerland’s political neutrality and high standards make it a preferred location for multinational Phase I and Phase II trials. Authorisation timelines are generally 30-90 days depending on trial complexity and IMP classification.
Medical Device Regulation in Switzerland
Switzerland aligned its medical device regulatory framework with the EU Medical Device Regulation (MDR, 2017/745) and the EU In Vitro Diagnostic Medical Device Regulation (IVDR, 2017/746) with effect from May 2021. The MepV/ODim transposes these EU frameworks into Swiss law.
Classification and Conformity Routes
| Device Class | Examples | Conformity Route |
|---|---|---|
| Class I (non-sterile, non-measuring) | Basic bandages, examination gloves | Self-declaration; notify Swissmedic |
| Class I (sterile or measuring function) | Sterile wound dressings, rulers | Notified body involvement for specific modules |
| Class IIa | Short-term implants, diagnostic ultrasound | Notified body certification required |
| Class IIb | Long-term implants, ventilators | Notified body certification required |
| Class III | Active implantables, coronary stents | Notified body certification + Swissmedic scrutiny |
| IVD Class A | General laboratory instruments | Self-declaration |
| IVD Class B/C/D | HIV tests, blood glucose meters, blood typing | Notified body certification required |
Switzerland recognises EU-notified bodies for device certification purposes. A CE mark issued by an EU-recognised notified body under MDR/IVDR supports the Swiss conformity pathway, provided the device is also registered in the Swiss medical device database (EUDAMED equivalent process applies).
Swiss Authorised Representative
Non-Swiss manufacturers placing devices on the Swiss market must appoint a Swiss Authorised Representative (CH-REP). The CH-REP is legally responsible for regulatory compliance in Switzerland, acts as the contact point for Swissmedic, and must be based in Switzerland. This requirement mirrors the EU Authorised Representative obligation and applies regardless of whether the manufacturer holds EU registration. The CH-REP must maintain technical documentation on Swiss soil and be reachable by Swissmedic during Swiss business hours. In practice, many foreign manufacturers underestimate the CH-REP role: it is not a postal address arrangement. The CH-REP assumes regulatory liability and must have personnel competent to handle Swissmedic enquiries about the specific device. Appointing a CH-REP without adequate technical capability is a compliance failure waiting to surface during a market surveillance action.
The Clock-Stop Problem: Why Timelines Slip
The most common cause of Swissmedic timeline overruns is not the agency’s processing speed — it is the applicant’s dossier quality.
When Swissmedic identifies a deficiency in a marketing authorisation dossier, it issues a “list of questions” (Mangelliste). The review clock stops entirely until the applicant provides a complete response. Each round of questions adds the response preparation time plus the time for Swissmedic to resume review. In practice:
- One round of questions: adds 3-6 months to the timeline
- Two rounds: adds 8-14 months
- Three or more rounds: the dossier may be refused and the applicant invited to withdraw and resubmit
For novel biologicals, two rounds of questions is the norm rather than the exception. A standard procedure that Swissmedic quotes at 12-18 months can realistically extend to 24-30 months if the dossier is incomplete or the clinical data package has gaps.
The practical fix: Engage regulatory affairs specialists who have submitted to Swissmedic before. A pre-submission meeting with Swissmedic (available for novel active substances and complex biologicals) allows the agency to flag potential issues before the clock starts. This meeting costs nothing beyond the preparation time, but it can prevent six months of delay.
The Swiss-EU Mutual Recognition Agreement
The Swiss-EU MRA on conformity assessment covers GMP inspections, batch release, and a number of conformity assessment procedures. In practical terms, this means:
- A GMP inspection by Swissmedic is recognised by EU competent authorities without re-inspection
- EU competent authority inspections of Swiss sites are recognised by Swissmedic
- Batch release conducted in Switzerland by a Qualified Person meets EU requirements for products exported to EU member states
Post-Brexit, the UK operates outside the Swiss-EU MRA. UK marketing authorisations granted by the MHRA are not automatically recognised in Switzerland, and vice versa. Companies with UK and Swiss market ambitions must plan two parallel regulatory submissions.
Why Switzerland’s Regulatory Environment Matters Commercially
A Swissmedic authorisation carries weight well beyond Swiss borders. Regulators in the Gulf, Southeast Asia, and Latin America routinely treat Swissmedic approval as a quality benchmark when evaluating market access applications. For companies that plan international commercialisation, obtaining Swiss authorisation early — even before pursuing US FDA or Japanese PMDA pathways — can shorten overall time to global market.
The Swiss pharmaceutical regulatory environment is also genuinely stable. Swissmedic’s procedures, inspection standards, and fee schedules are published in advance and applied consistently. That predictability has real value in a sector where regulatory surprise is expensive. Companies establishing operations in Switzerland benefit from FINMA licensing structures that complement the Swissmedic regulatory framework for financial aspects of pharmaceutical operations.
For a broader overview, see our guide to Industry-Specific Licences.
Frequently Asked Questions
Does EU marketing authorisation automatically apply in Switzerland?
No. Switzerland is not an EU member state. A European Medicines Agency (EMA) centralised authorisation or an EU member state national authorisation does not grant automatic access to the Swiss market. A separate Swissmedic application is required. In practice, companies often submit in parallel or use the Swiss-EU MRA to streamline GMP and quality recognition, but the authorisation dossier is a distinct submission.
Can a foreign pharmaceutical company apply to Swissmedic directly?
Yes, but the marketing authorisation holder must have a legal address in Switzerland (or the European Economic Area in certain circumstances). Foreign companies without a Swiss presence typically establish a Swiss subsidiary or appoint a local regulatory affairs representative before submitting. The entity setup should be completed well before the Swissmedic submission — the agency requires a valid Swiss UID (Unternehmens-Identifikationsnummer) at the time of filing, and obtaining one requires a registered company in the commercial register. The formation-to-UID timeline is typically 3-5 weeks. See our guide to company formation in Switzerland for the structural options.
How does Switzerland handle biosimilars?
Swissmedic has an established biosimilar authorisation pathway aligned with EMA guidelines. The applicant must demonstrate comparability to a reference biological product already authorised by Swissmedic (not simply by EMA). Data requirements include analytical comparability studies, non-clinical bridging data, and at minimum one comparative clinical pharmacokinetic study. The simplified procedure applies, with typical timelines of 12-15 months for complex biologicals.
How much does a Swissmedic marketing authorisation cost?
Fees depend on the procedure type and complexity. A standard procedure for a new active substance costs CHF 80,000-200,000. Simplified procedures for well-established substances or generics range from CHF 15,000-50,000. Additional expert assessment, clock-stop periods for dossier queries, and post-authorisation variation fees are charged separately. Budget for the full range — underprepared dossiers attract queries that extend timelines and increase costs.
What is the timeline for Swissmedic marketing authorisation?
Standard procedure for new active substances takes 12-18 months. Accelerated procedure for urgent public health needs takes 6-12 months. Simplified and generic procedures also take 6-12 months. These timelines assume a complete dossier — deficiencies trigger clock-stops that can add 3-6 months to the process.
Does Swissmedic recognise GMP inspections from EU authorities?
Yes, under the Swiss-EU Mutual Recognition Agreement (MRA). GMP inspections by EU competent authorities are recognised by Swissmedic without re-inspection, and vice versa. This bilateral recognition significantly reduces the regulatory burden for companies manufacturing in both jurisdictions. Post-Brexit, UK MHRA inspections are not covered by this arrangement.
What is a Swiss Authorised Representative (CH-REP) for medical devices?
Non-Swiss manufacturers placing medical devices on the Swiss market must appoint a CH-REP based in Switzerland. The CH-REP is legally responsible for regulatory compliance, acts as the contact point for Swissmedic, and must maintain technical documentation. This requirement mirrors the EU Authorised Representative obligation under MDR and applies regardless of whether the manufacturer holds EU registration.
Can I conduct clinical trials in Switzerland without Swissmedic approval?
No. Clinical trials conducted in Switzerland require dual authorisation from Swissmedic and the relevant cantonal ethics committee. Both must approve before the trial can start. Swissmedic reviews the quality and pre-clinical/clinical data package, while the ethics committee reviews the protocol, patient information, and consent procedures. Authorisation timelines are typically 30-90 days.
How often must a Swissmedic marketing authorisation be renewed?
Every five years. Authorisation holders must submit a renewal application demonstrating ongoing compliance with pharmacovigilance obligations, updated safety data, and any formulation or labelling changes approved during the authorisation period. Failure to renew results in the authorisation lapsing and the product being withdrawn from the Swiss market.
What happens if I sell therapeutic products in Switzerland without a Swissmedic licence?
Operating without the required Swissmedic authorisation is a criminal offence under the Therapeutic Products Act (HMG/LPTh), not merely a regulatory infraction. Penalties include fines and imprisonment. Swissmedic actively monitors the Swiss market and investigates unauthorised distribution of therapeutic products, including online sales channels.
Next Steps: Request a Free Assessment
Swissmedic licensing is a specialist regulatory and legal task. The dossier requirements are substantial, the procedures are sequential, and errors in the initial submission add months to the timeline.
Morgan Hartley Consulting works with pharmaceutical companies, medical device manufacturers, and biotech startups to structure Swissmedic applications, advise on entity setup, and coordinate with regulatory affairs specialists. We also advise on the broader Swiss business licensing framework that governs market entry across regulated sectors.
For a direct conversation about your product and the applicable authorisation pathway, request a free assessment.
Morgan Hartley Consulting (Morgan Hartley Consulting) Baarerstrasse 135, 6300 Zug, Switzerland Phone: +41 44 51 52 592 | Email: [email protected]